This academic-industry partnership reflects the need for a multidisciplinary approach to innovation in cell and gene therapy manufacturing.
EVE is a deep generative model combining evolutionary and human population data to estimate variant deleteriousness on a proteome-wide scale.
The U.S. is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing, and commercial sites.
The U.S. Pharmacopeia has created new standards to support the emerging field of advanced cell and gene therapies.
Precipitation-based purification method could replace current Protein A–reliant methods, significantly reducing manufacturing costs of mAbs.
Sustainable bioprocessing boosts cyanobacterial pigment production for advanced biomedical, imaging, and commercial applications.
Multiple microbial communities populate cleanrooms, regardless of grade, and aren’t detected by standard monitoring methods.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback